2026-07-23T17:43:02Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/186242024-02-27T15:07:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982
Repisalud author Mena-Vázquez, Natalia author García-Studer, Aimara author Rojas-Gimenez, Marta author Romero-Barco, Carmen María author Manrique-Arija, Sara author Mucientes, Arkaitz author Velloso-Feijoo, María Luisa author Godoy-Navarrete, Francisco Javier author Morales-Garrido, Pilar author Redondo-Rodríguez, Rocío author Ordoñez-Cañizares, M C author Ortega-Castro, Rafaela author Lisbona-Montañez, Jose Manuel author Hidalgo Conde, Ana author Arnedo Díez de Los Ríos, Rocío author Cabrera César, Eva author Espildora, Francisco author Aguilar-Hurtado, María Carmen author Añón-Oñate, Isabel author Ureña-Garnica, Inmaculada author Fernández-Nebro, Antonio 2024-02-27T15:07:04Z 2024-02-27T15:07:04Z 2022-04-26 10.3390/jcm11092437 2077-0383 Journal of clinical medicine http://hdl.handle.net/10668/21278 35566564 http://hdl.handle.net/20.500.12105/18624 Objectives: To describe the frequency of COVID-19 and the effect of vaccination in patients with interstitial lung disease and systemic autoimmune disease (ILD-SAD) and to identify factors associated with infection and severity of COVID-19. Methods: We performed a cross-sectional multicenter study of patients with ILD-SAD followed between June and October 2021. The main variable was COVID-19 infection confirmed by a positive polymerase chain reaction (PCR) result for SARS-CoV-2. The secondary variables included severity of COVID-19, if the patient had to be admitted to hospital or died of the disease, and vaccination status. Other variables included clinical and treatment characteristics, pulmonary function and high-resolution computed tomography. Two logistic regression was performed to explore factors associated with “COVID-19” and “severe COVID-19”. Results: We included 176 patients with ILD-SAD: 105 (59.7%) had rheumatoid arthritis, 49 (27.8%) systemic sclerosis, and 22 (12.54%) inflammatory myopathies. We recorded 22/179 (12.5%) SARS-CoV-2 infections, 7/22 (31.8%) of them were severe and 3/22 (13.22%) died. As to the vaccination, 163/176 (92.6%) patients received the complete doses. The factors associated with SARS-CoV-2 infection were FVC (OR (95% CI), 0.971 (0.946−0.989); p = 0.040), vaccination (OR (95% CI), 0.169 (0.030−0.570); p = 0.004), and rituximab (OR (95% CI), 3.490 (1.129−6.100); p = 0.029). The factors associated with severe COVID-19 were the protective effect of the vaccine (OR (95% CI), 0.024 (0.004−0.170); p < 0.001) and diabetes mellitus (OR (95% CI), 4.923 (1.508−19.097); p = 0.018). Conclusions: Around 13% of patients with ILD-SAD had SARS-CoV-2 infection, which was severe in approximately one-third. Most patients with severe infection were not fully vaccinated. eng SARS-CoV-2 infections interstitial lung disease (ILD) systemic autoimmune disease (SAD) vaccination COVID-19 Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease. research article